You may be a good candidate for Semaglutide (GLP-1) or Tirzepatide (GLP-1/GLP-2) injections if: You have a BMI of 27 or higher with weight-related health concerns (such as high blood pressure, elevated cholesterol, or type 2 diabetes)
This maximizes tolerance but significantly extends time to optimal dosing, potentially losing patients to frustration before benefits fully manifest
UK Evidence and Guidance Retatrutide safety in women is a pressing question as this investigational triple hormone receptor agonist generates growing interest for obesity and type 2 diabetes treatment
A: investigation and methodology
GLP-1 receptor agonists, a cornerstone of modern medical weight loss, offer a host of benefits
Knowing what to expect at each phase prevents two common mistakes: getting discouraged early when the scale moves slowly, and getting impatient mid-treatment when the rate of loss naturally slows